These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 29550843

  • 1. 18F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body 131I scan.
    Liu J, Liu B, Yu Y, Chao F, Liu Y, Han X.
    Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843
    [Abstract] [Full Text] [Related]

  • 2. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 3. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T.
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [Abstract] [Full Text] [Related]

  • 4. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Oct; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 5. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 7. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT.
    Seo JH, Lee SW, Ahn BC, Lee J.
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):558-63. PubMed ID: 19744107
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A.
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [Abstract] [Full Text] [Related]

  • 9. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A, Kaznowski J, Wolinski K, Jodlowska E, Michaliszyn P, Kubiak K, Czepczynski R, Ruchala M.
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [Abstract] [Full Text] [Related]

  • 10. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 Sep; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

  • 11. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M.
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [Abstract] [Full Text] [Related]

  • 12. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M, Sager S, Halac M, Sonmezoglu K.
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [Abstract] [Full Text] [Related]

  • 13. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E, Soydal C, Araz M, Aras G, Ibis E.
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level.
    Qiu ZL, Wei WJ, Shen CT, Song HJ, Zhang XY, Sun ZK, Luo QY.
    Sci Rep; 2017 Jun 06; 7(1):2849. PubMed ID: 28588229
    [Abstract] [Full Text] [Related]

  • 15. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan 06; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 16. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar 06; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 17. Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer.
    Chai H, Zhang H, Yu YL, Gao YC.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun 06; 37(3):429-432. PubMed ID: 28585147
    [Abstract] [Full Text] [Related]

  • 18. The Diagnostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-Analysis.
    Bang JI, Park S, Kim K, Seo Y, Chong A, Hong CM, Choi M, Lee SW, Oh SW.
    Thyroid; 2023 Oct 06; 33(10):1224-1236. PubMed ID: 37597200
    [Abstract] [Full Text] [Related]

  • 19. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.
    Rev Esp Med Nucl Imagen Mol; 2012 Oct 06; 31(6):315-21. PubMed ID: 23084014
    [Abstract] [Full Text] [Related]

  • 20. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody.
    Liu Y.
    Nucl Med Commun; 2016 Jun 06; 37(6):577-82. PubMed ID: 26813991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.